Victory Capital Management
DNLI icon

Victory Capital Management’s Denali Therapeutics DNLI Stock Holding History

Victory Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$442K Buy
17,197
+1,003
+6% +$20.6K ﹤0.01% 2095
2026
Q1 		$311K Buy
16,194
+1,130
+8% +$22.5K ﹤0.01% 2119
2025
Q4 		$249K Hold
15,064
– – ﹤0.01% 2153
2025
Q3 		$219K Sell
15,064
-30,552
-67% -$439K ﹤0.01% 2207
2025
Q2 		$638K Buy
45,616
+3,989
+10% +$56.1K ﹤0.01% 2006
2025
Q1 		$566K Buy
41,627
+3,119
+8% +$59.8K ﹤0.01% 1996
2024
Q4 		$785K Sell
38,508
-1,392
-3% -$35.6K ﹤0.01% 1905
2024
Q3 		$1.16M Buy
39,900
+24,767
+164% +$614K ﹤0.01% 1721
2024
Q2 		$351K Buy
15,133
+390
+3% +$7.49K ﹤0.01% 2064
2024
Q1 		$303K Sell
14,743
-605
-4% -$11.4K ﹤0.01% 2120
2023
Q4 		$329K Buy
15,348
+3,267
+27% +$64.7K ﹤0.01% 2100
2023
Q3 		$249K Buy
12,081
+630
+6% +$16K ﹤0.01% 2163
2023
Q2 		$338K Sell
11,451
-267
-2% -$7.51K ﹤0.01% 2088
2023
Q1 		$270K Sell
11,718
-1,538
-12% -$42.3K ﹤0.01% 2171
2022
Q4 		$369K Buy
13,256
+1,631
+14% +$48.5K ﹤0.01% 2112
2022
Q3 		$357K Buy
11,625
+742
+7% +$24.1K ﹤0.01% 2186
2022
Q2 		$320K Hold
10,883
– – ﹤0.01% 2214
2022
Q1 		$259K Sell
10,883
-1,198
-10% -$41.2K ﹤0.01% 2345
2021
Q4 		$539K Sell
12,081
-9,627
-44% -$456K ﹤0.01% 2111
2021
Q3 		$1.09M Sell
21,708
-20,413
-48% -$1.15M ﹤0.01% 1820
2021
Q2 		$3.3M Buy
42,121
+3,766
+10% +$233K ﹤0.01% 1482
2021
Q1 		$2.19M Buy
38,355
+19,788
+107% +$1.32M ﹤0.01% 1627
2020
Q4 		$1.55M Buy
18,567
+6,099
+49% +$369K ﹤0.01% 1596
2020
Q3 		$447K Sell
12,468
-671
-5% -$20.2K ﹤0.01% 2004
2020
Q2 		$318K Sell
13,139
-484
-4% -$11.4K ﹤0.01% 2158
2020
Q1 		$239K Buy
13,623
+36
+0.3% +$751 ﹤0.01% 2099
2019
Q4 		$237K Sell
13,587
-1,848
-12% -$30.8K ﹤0.01% 2269
2019
Q3 		$236K Buy
+15,435
New +$295K ﹤0.01% 2164

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Victory Capital Management's DNLI Position: Q2 2026 in Review

Victory Capital Management increased its Denali Therapeutics (DNLI) stake by 6.2% in Q2 2026, buying an estimated $20.6K and bringing the position to 17,197 shares worth $442K. The position accounts for ﹤0.01% of the portfolio, ranked #2095.

Victory Capital Management first reported a position in DNLI in Q3 2019 and has held it in 28 quarters since. The position peaked at $3.3M in Q2 2021. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Victory Capital Management held 17,197 shares of Denali Therapeutics worth $442K as of Q2 2026.
  • Victory Capital Management bought 1,003 Denali Therapeutics shares in Q2 2026, an estimated $20.6K.
  • Denali Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #2095 holding.
  • Victory Capital Management first reported a position in Denali Therapeutics in Q3 2019 and has held it in 28 quarters since.
  • Victory Capital Management's Denali Therapeutics position peaked at $3.3M in Q2 2021.
  • 294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.